Table 1

Baseline data of included patients

Subcutaneous groupIntravenous group
Age79 (7.3)83 (6.9)
Sex (female)a16 (66%)17 (62%)
Site of recruitmentaER:
Orto:
Short-term:
7 (29%)
14 (58%)
3 (13%)
7 (26%)
18 (67%)
2 (7%)
Number of known comorbidities4.6 (1.9)3.9 (1.4)
Charlson Comorbidity Index [22]
Median (25–75 range)
1 (0–2)0 (0–2)
Treated with anti-coagulant medicationa8 (35%)9 (33%)
Systolic Blood Pressure (mm Hg)136 (28)129 (21)
Diastolic blood Pressure (mm Hg)68 (10)69 (12)
Pulse (/min)83 (18)79 (12)
Hemoglobin (g/dl)b10.5 (2.3)11.3 (2.5)
Sodium (mEq/l)137 (3.5)137 (3.7)
Potassium (mEq/l)3.8 (0.6)3.8 (0.6)
Urea (mg/dl)c50 (25)56 (46)
Creatinine (mg/dl)d1.1 (0.46)1.0 (0.46)
eGFR (ml/min/1.73m2)61 (23)63 (24)
Albumin (g/dl)e2.7 (0.38)2.9 (0.43)
Osmolality (mmol/kg)294 (18)290 (11)
Subcutaneous groupIntravenous group
Age79 (7.3)83 (6.9)
Sex (female)a16 (66%)17 (62%)
Site of recruitmentaER:
Orto:
Short-term:
7 (29%)
14 (58%)
3 (13%)
7 (26%)
18 (67%)
2 (7%)
Number of known comorbidities4.6 (1.9)3.9 (1.4)
Charlson Comorbidity Index [22]
Median (25–75 range)
1 (0–2)0 (0–2)
Treated with anti-coagulant medicationa8 (35%)9 (33%)
Systolic Blood Pressure (mm Hg)136 (28)129 (21)
Diastolic blood Pressure (mm Hg)68 (10)69 (12)
Pulse (/min)83 (18)79 (12)
Hemoglobin (g/dl)b10.5 (2.3)11.3 (2.5)
Sodium (mEq/l)137 (3.5)137 (3.7)
Potassium (mEq/l)3.8 (0.6)3.8 (0.6)
Urea (mg/dl)c50 (25)56 (46)
Creatinine (mg/dl)d1.1 (0.46)1.0 (0.46)
eGFR (ml/min/1.73m2)61 (23)63 (24)
Albumin (g/dl)e2.7 (0.38)2.9 (0.43)
Osmolality (mmol/kg)294 (18)290 (11)

Abbreviations: ER: Emergency room, Orto: Orthopedic ward;

Unless otherwise indicated, data are expressed as mean (standard deviation)

aData expressed as number (per cent),

bTo convert the values for haemoglobin to mmol/l multiply by 0.62,

cTo convert the values for urea to mmol/divide by 6,

dTo convert the values for creatinine to μmol/l multiply by 88.42,

eTo convert the values of albumin to g/l multiply by 10.

Table 1

Baseline data of included patients

Subcutaneous groupIntravenous group
Age79 (7.3)83 (6.9)
Sex (female)a16 (66%)17 (62%)
Site of recruitmentaER:
Orto:
Short-term:
7 (29%)
14 (58%)
3 (13%)
7 (26%)
18 (67%)
2 (7%)
Number of known comorbidities4.6 (1.9)3.9 (1.4)
Charlson Comorbidity Index [22]
Median (25–75 range)
1 (0–2)0 (0–2)
Treated with anti-coagulant medicationa8 (35%)9 (33%)
Systolic Blood Pressure (mm Hg)136 (28)129 (21)
Diastolic blood Pressure (mm Hg)68 (10)69 (12)
Pulse (/min)83 (18)79 (12)
Hemoglobin (g/dl)b10.5 (2.3)11.3 (2.5)
Sodium (mEq/l)137 (3.5)137 (3.7)
Potassium (mEq/l)3.8 (0.6)3.8 (0.6)
Urea (mg/dl)c50 (25)56 (46)
Creatinine (mg/dl)d1.1 (0.46)1.0 (0.46)
eGFR (ml/min/1.73m2)61 (23)63 (24)
Albumin (g/dl)e2.7 (0.38)2.9 (0.43)
Osmolality (mmol/kg)294 (18)290 (11)
Subcutaneous groupIntravenous group
Age79 (7.3)83 (6.9)
Sex (female)a16 (66%)17 (62%)
Site of recruitmentaER:
Orto:
Short-term:
7 (29%)
14 (58%)
3 (13%)
7 (26%)
18 (67%)
2 (7%)
Number of known comorbidities4.6 (1.9)3.9 (1.4)
Charlson Comorbidity Index [22]
Median (25–75 range)
1 (0–2)0 (0–2)
Treated with anti-coagulant medicationa8 (35%)9 (33%)
Systolic Blood Pressure (mm Hg)136 (28)129 (21)
Diastolic blood Pressure (mm Hg)68 (10)69 (12)
Pulse (/min)83 (18)79 (12)
Hemoglobin (g/dl)b10.5 (2.3)11.3 (2.5)
Sodium (mEq/l)137 (3.5)137 (3.7)
Potassium (mEq/l)3.8 (0.6)3.8 (0.6)
Urea (mg/dl)c50 (25)56 (46)
Creatinine (mg/dl)d1.1 (0.46)1.0 (0.46)
eGFR (ml/min/1.73m2)61 (23)63 (24)
Albumin (g/dl)e2.7 (0.38)2.9 (0.43)
Osmolality (mmol/kg)294 (18)290 (11)

Abbreviations: ER: Emergency room, Orto: Orthopedic ward;

Unless otherwise indicated, data are expressed as mean (standard deviation)

aData expressed as number (per cent),

bTo convert the values for haemoglobin to mmol/l multiply by 0.62,

cTo convert the values for urea to mmol/divide by 6,

dTo convert the values for creatinine to μmol/l multiply by 88.42,

eTo convert the values of albumin to g/l multiply by 10.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close